Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
The states where Polio vaccine drops will be conducted includes: Bihar, Chandigarh, Delhi, Gujarat, Haryana, Jharkhand, Maharashtra, Punjab, Rajasthan, Uttarakhand, and West Bengal
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
Subscribe To Our Newsletter & Stay Updated
